Gut bacteria may worsen liver disease – new study investigates
NCT ID NCT02400216
First seen Jun 27, 2026 · Last updated Sep 17, 2026 · Updated 4 times
Summary
This study looked at how bacteria from the gut might travel to the liver and make liver disease worse in people with hepatitis C. Thirty adults with stable liver disease took part. Researchers used blood tests, MRI scans, and liver tissue samples to measure bacterial movement and liver function.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- dual cholate
- What this could lead to
- If successful, this could help doctors better understand how gut bacteria affect liver disease in people with hepatitis C.
- What could go wrong
- This is a small, observational study with only 30 participants. It is not testing a treatment, so it will not directly improve health.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
30 people
The number who actually took part.
- Started
-
May 2015
- Finished
-
Apr 2017
- Lead sponsor
-
A government research agency
The lead sponsor is the US National Institutes of Health.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Primary clinical patients with chronic HCV infection divided into 2 groups according to liver fibrosis stage.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
* INCLUSION CRITERIA: 1. All age greater than 18 male or female 2. Capacity to provide written informed consent 3. Evidence of HCV RNA in 2 serum samples at least 6 months apart. 4. All HCV genotypes 5. Liver biopsy in the last 2 years prior to enrollment showing Ishak fibrosis score of either 0-1 or 5-6. An alternative to liver biopsy will be a Fibroscan study performed in the 6 months prior to study enrollment showing a score of either kPa \<7 or above 13. 6. Child-Pugh score less than or equal to 6 7. Prior to each liver biopsy and portal vein cannulation procedure, blood will be drawn for CBC, PT/INR \& acute care panel. EXCLUSION CRITERIA: 1. Pregnant women or females at child bearing age not taking measures to prevent pregnancy during the period of study 2. Patients currently on treatment for hepatitis C 3. Clinical, serologic or histopathologic evidence supporting other etiologies of chronic liver disease besides HCV 4. Current or past clinical evidence of decompensated liver disease (e.g. ascites, bleeding esophageal varices, spontaneous bacterial peritonitis, encephalopathy etc.) 5. Cross sectional liver imaging study from the past 6 months showing a focal lesion suspicious of hepatocellular carcinoma and/or alpha-fetoprotein level greater than 200 ng/mL. 6. Patients with active bacterial, viral or fungal, systemic or localized infection. 7. Antibiotic treatment 30 days prior to study enrollment 8. History of chronic inflammatory diseases of the bowel (Crohn s disease, Ulcerative colitis and celiac disease) 9. History of congestive heart failure of moderate to severe degree. 10. History of non-cirrhotic portal hypertension or portal vein thrombosis 11. Patients with severe allergic reactions to iodine contrast, which cannot be controlled by premedication with antihistamines and steroids. 12. EXCLUSION CRITERIA FOR MRI: 12.1 Subjects with contraindication to MRI scanning. These contraindications include but are not limited to the following devices or conditions: \<TAB\>a. Implanted cardiac pacemaker or defibrillator \<TAB\>b. Cochlear Implants \<TAB\>c. Ocular foreign body (e.g. metal shavings) \<TAB\>d. Embedded shrapnel fragments \<TAB\>e. Central nervous system aneurysm clips \<TAB\>f. Implanted neural stimulator \<TAB\>g. Medical infusion pumps \<TAB\>h. Any implanted device that is incompatible with MRI. 12.2 Unsatisfactory performance status as judged by the referring physician such that the subject could not tolerate an MRI scan. Examples of medical conditions that would not be accepted would include unstable angina and dyspnea at rest. 12.3 Subjects requiring sedation for MRI studies. 12.4 Subjects with a condition precluding entry into the scanner (e.g. morbid obesity, claustrophobia, etc.). 12.5 Pregnant or lactating women. 12.6 Subjects with severe back-pain or motion disorders who will be unable to tolerate supine positioning within the MRI scanner and hold still for the duration of the examination. 12.7 For Gadolinium based and SPIO MRI Use: \<TAB\>a. History of severe allergic reaction to these contrast agents despite the use of premeditation with an anti-histaminic and cortisone. \<TAB\>b. eGFR \< 60 ml/min/1.73m\^2 13. Absolute neutrophil count below 1000/mm\^3, Hemoglobin level below 10.0 g/dl or platelet count lower than 70,000/mm\^3. 14. INR greater than or equal to 1.5, PTT greater than or equal to 1.3 times control and/or any known history of disease associated with increased bleeding diathesis. 15. Serum creatinine greater than or equal to 2.0 mg/dl unless the measured creatinine clearance is greater than 60 mL/min
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Cirrhosis are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Sound waves may replace the needle in liver scarring tests
- Ultrasound may replace invasive test for dangerous liver complication
- Could a wearable zapper quiet cirrhosis pain without drugs?
- A needle through the gut could replace the standard liver pressure test
- Can two experimental drugs be used safely in people with cirrhosis?
- Can bedside ultrasound guide fluid treatment for cirrhosis patients?